title: Genome wide proteomics of ERBB2 and EGFR and other oncogenic pathways in inflammatory breast cancer.
abstract: In this study we selected three breast cancer cell lines (SKBR3, SUM149 and SUM190) with different oncogene expression levels involved in ERBB2 and EGFR signaling pathways as a model system for the evaluation of selective integration of subsets of transcriptomic and proteomic data. We assessed the oncogene status with reads per kilobase per million mapped reads (RPKM) values for ERBB2 (14.4, 400, and 300 for SUM149, SUM190, and SKBR3, respectively) and for EGFR (60.1, not detected, and 1.4 for the same 3 cell lines). We then used RNA-Seq data to identify those oncogenes with significant transcript levels in these cell lines (total 31) and interrogated the corresponding proteomics data sets for proteins with significant interaction values with these oncogenes. The number of observed interactors for each oncogene showed a significant range, e.g., 4.2% (JAK1) to 27.3% (MYC). The percentage is measured as a fraction of the total protein interactions in a given data set vs total interactors for that oncogene in STRING (Search Tool for the Retrieval of Interacting Genes/Proteins, version 9.0) and I2D (Interologous Interaction Database, version 1.95). This approach allowed us to focus on 4 main oncogenes, ERBB2, EGFR, MYC, and GRB2, for pathway analysis. We used bioinformatics sites GeneGo, PathwayCommons and NCI receptor signaling networks to identify pathways that contained the four main oncogenes and had good coverage in the transcriptomic and proteomic data sets as well as a significant number of oncogene interactors. The four pathways identified were ERBB signaling, EGFR1 signaling, integrin outside-in signaling, and validated targets of C-MYC transcriptional activation. The greater dynamic range of the RNA-Seq values allowed the use of transcript ratios to correlate observed protein values with the relative levels of the ERBB2 and EGFR transcripts in each of the four pathways. This provided us with potential proteomic signatures for the SUM149 and 190 cell lines, growth factor receptor-bound protein 7 (GRB7), Crk-like protein (CRKL) and Catenin delta-1 (CTNND1) for ERBB signaling; caveolin 1 (CAV1), plectin (PLEC) for EGFR signaling; filamin A (FLNA) and actinin alpha1 (ACTN1) (associated with high levels of EGFR transcript) for integrin signalings; branched chain amino-acid transaminase 1 (BCAT1), carbamoyl-phosphate synthetase (CAD), nucleolin (NCL) (high levels of EGFR transcript); transferrin receptor (TFRC), metadherin (MTDH) (high levels of ERBB2 transcript) for MYC signaling; S100-A2 protein (S100A2), caveolin 1 (CAV1), Serpin B5 (SERPINB5), stratifin (SFN), PYD and CARD domain containing (PYCARD), and EPH receptor A2 (EPHA2) for PI3K signaling, p53 subpathway. Future studies of inflammatory breast cancer (IBC), from which the cell lines were derived, will be used to explore the significance of these observations.
authors: Barnett Institute and Department of Chemistry and Chemical Biology, Northeastern University, 360 Huntington Avenue, Boston, Massachusetts 02115, United States.
authors: Emma Yue
authors: EY
authors: Zhang
authors: Massimo
authors: M
authors: Cristofanilli
authors: Fredika
authors: F
authors: Robertson
authors: James M
authors: JM
authors: Reuben
authors: Zhaomei
authors: Z
authors: Mu
authors: Ronald C
authors: RC
authors: Beavis
authors: Hogune
authors: H
authors: Im
authors: Michael
authors: M
authors: Snyder
authors: Matan
authors: M
authors: Hofree
authors: Trey
authors: T
authors: Ideker
authors: Gilbert S
authors: GS
authors: Omenn
authors: Susan
authors: S
authors: Fanayan
authors: Seul-Ki
authors: SK
authors: Jeong
authors: Young-Ki
authors: YK
authors: Paik
authors: Anna Fan
authors: AF
authors: Zhang
authors: Shiaw-Lin
authors: SL
authors: Wu
authors: William S
authors: WS
authors: Hancock
mesh_terms: D001943:Breast Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D066246:ErbB Receptors / Q000235:genetics* / Q000378:metabolism; D005260:Female; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D055106:Genome-Wide Association Study; D006801:Humans; D007249:Inflammation; D058977:Molecular Sequence Annotation; D009363:Neoplasm Proteins / Q000235:genetics* / Q000378:metabolism; D040901:Proteomics; D012333:RNA, Messenger / Q000235:genetics* / Q000378:metabolism; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics* / Q000378:metabolism; D015398:Signal Transduction
chemical_list: D066246:ErbB Receptors; D009363:Neoplasm Proteins; D012333:RNA, Messenger; D018719:Erb-b2 Receptor Tyrosine Kinases; C512478:EGFR protein, human; C508053:ERBB2 protein, human
references: Breast Cancer Res Treat. 2012 Jan;131(2):371-83
references: 21956210
references: Genome Res. 2007 Sep;17(9):1296-303
references: 17675364
references: Oncogene. 1997 Dec 4;15(23):2841-8
references: 9419975
references: EMBO J. 1994 Mar 15;13(6):1331-40
references: 7907978
references: Breast Cancer Res. 2008;10(6):R101
references: 19055754
references: Breast Cancer Res. 2008;10(6):217
references: 19144211
references: Cell. 2012 Mar 16;148(6):1293-307
references: 22424236
references: Cell Oncol. 2007;29(6):467-76
references: 18032823
references: Cancer Lett. 1993 Feb;68(2-3):95-104
references: 8443798
references: Mol Cell Proteomics. 2013 May;12(5):1239-49
references: 23371026
references: Nat Rev Cancer. 2003 Jan;3(1):11-22
references: 12509763
references: Am J Pathol. 2010 Mar;176(3):1203-14
references: 20075200
references: Cancer Biomark. 2012;11(2-3):75-88
references: 23011154
references: J Biol Chem. 2008 Jan 11;283(2):739-50
references: 17942395
references: Nat Rev Cancer. 2004 Mar;4(3):177-83
references: 14993899
references: Oncogene. 2004 Jan 29;23(4):1010-3
references: 14647448
references: J Proteome Res. 2008 Apr;7(4):1542-54
references: 18336003
references: Mol Cancer Res. 2007 Mar;5(3):283-93
references: 17374733
references: Proc Natl Acad Sci U S A. 2000 May 23;97(11):6049-54
references: 10811911
references: J Biol Chem. 1993 Feb 5;268(4):2924-31
references: 7679104
references: J Clin Oncol. 2007 Nov 20;25(33):5287-312
references: 17954709
references: Clin Cancer Res. 2008 Jun 1;14(11):3319-26
references: 18519759
references: Cancer Res. 2001 Nov 15;61(22):8235-40
references: 11719455
references: Anal Chem. 2011 Jun 15;83(12):4845-54
references: 21513341
references: Oncogene. 2000 Dec 27;19(56):6550-65
references: 11426640
references: Exp Cell Res. 2008 Sep 10;314(15):2762-73
references: 18598695
references: Oncogene. 2003 May 29;22(22):3475-88
references: 12776200
references: Proteomics. 2005 Feb;5(2):566-71
references: 15627964
references: Br J Cancer. 1999 Dec;81(8):1328-34
references: 10604729
references: Breast Cancer Res Treat. 2006 Sep;99(1):85-90
references: 16541313
references: Cancer Biol Ther. 2009 Aug;8(15):1470-7
references: 19483462
references: Mol Biol Cell. 2002 May;13(5):1449-61
references: 12006644
references: Cancer Cell. 2004 Apr;5(4):317-28
references: 15093539
references: BMC Bioinformatics. 2012 Jul 28;13:182
references: 22838965
references: Semin Cancer Biol. 2006 Jun;16(3):214-24
references: 16698281
references: J Proteome Res. 2011 Feb 4;10(2):656-68
references: 21067242
references: Mol Cell Proteomics. 2008 Dec;7(12):2373-85
references: 18644780
references: BMC Cancer. 2008 Dec 06;8:363
references: 19061514
references: Genome Biol. 2003;4(9):117
references: 12952525
references: Clin Chem. 2006 Oct;52(10):1897-905
references: 16916992
references: Breast Cancer Res Treat. 2008 Sep;111(1):27-44
references: 17922188
references: Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8933-8
references: 12853564
references: Nat Biotechnol. 2012 Nov;30(11):1065-7
references: 23138303
references: Nat Methods. 2008 Jul;5(7):621-8
references: 18516045
references: J Clin Pathol. 2008 Jul;61(7):856-62
references: 18381381
references: J Chromatogr A. 2010 May 7;1217(19):3307-15
references: 19782370
references: Semin Cancer Biol. 1999 Apr;9(2):125-38
references: 10202134
references: Mol Cell Proteomics. 2006 Sep;5(9):1610-27
references: 16799092
references: Mol Biol Evol. 2004 Feb;21(2):236-9
references: 14595094
references: Proc Natl Acad Sci U S A. 2006 Nov 21;103(47):17921-6
references: 17101988
references: Tumour Biol. 2011 Jun;32(3):441-50
references: 21153724
references: Breast Cancer Res Treat. 2003 Aug;80(3):353-61
references: 14503808
references: Breast Cancer Res Treat. 2003 Apr;78(3):285-7
references: 12755487
references: Proteomics. 2003 Jun;3(6):1037-46
references: 12833528
references: Mol Endocrinol. 2011 Sep;25(9):1499-512
references: 21700719
references: Br J Cancer. 2004 Aug 16;91(4):795-802
references: 15280923
references: Oncogene. 2009 Sep 10;28(36):3188-96
references: 19633686